PQA 06 - PQA 06: Genitourinary Cancer, Gynecological Cancer, and Health Care Access and Engagement

Presentations

• 02:15pm - 03:30pm ET

  Unknown Causes of Death in Localized Prostate Cancer: Long-Term Data from Two Phase III Trials

  Speaker: Abdenour Nabid, MD - CHUS, Sherbrooke
• 02:15pm - 03:30pm ET

  The Utilization of Dosimetry with Lu-177-PSMA-617 Radiopharmaceutical Treatments: Does Dosimetry Affect Treatment Change?

  Speaker: Caryn Cobb, MD - University of Pittsburgh, UPMC Hillman Cancer Center, Pittsburgh
• 02:15pm - 03:30pm ET

  Low-Dose-Rate Brachytherapy for Focal Salvage of Prostate Cancer Local Recurrence Using Scintigraphic Guidance

  Speaker: Jay Ciezki, MD - Cleveland Clinic, Cleveland
• 02:15pm - 03:30pm ET

  Updated Results of a Phase I Trial of a Prostatic Urethral Lift Implant with SAbR for Men with Prostate Cancer and Benign Prostatic Hyperplasia

  Speaker: Reena Kudchadker, BS - UT Southwestern Medical Center, Dallas
• 02:15pm - 03:30pm ET

  SOLACE: A Phase 1 Pharmacokinetic, Dosimetry, Safety and Dose Optimization Study for a Single Dose of ¹⁵³Sm-DOTMP to Treat Metastatic Bone Pain

  Speaker: David Cade, MD - Telix Pharmaceuticals, Fishers
• 02:15pm - 03:30pm ET

  Rectal Spacing in Large-to-Very-Large Prostates: Balloon vs. Hydrogel Spacer Quality and OAR Dose

  Speaker: Shawn Zimberg, MD - Advanced Radiation Centers of New York, North Hills
• 02:15pm - 03:30pm ET

  Neutron Radiotherapy with Concurrent Checkpoint Inhibitor in Patients with Advanced Urothelial Carcinoma (aUC): Results from a Phase II Clinical Trial

  Speaker: Ting Martin Ma, MD, PhD - University of Washington, Seattle
• 02:15pm - 03:30pm ET

  Evaluation of Organ at Risk Dose Variation under ATP only Workflow Compared with ATS in MRI Guided Prostate SBRT

  Speaker: Swarupa Mitra, MD - Rajiv Gandhi Cancer Institute & Research Centre, Delhi
• 02:15pm - 03:30pm ET

  Stereotactic Body Radiotherapy (SBRT) Re-Irradiation for Local Recurrence of Prostate Cancer: A Multi-Institutional Experience in Uruguay

  Speaker: Mauricio Luongo, - Consultorio Oncologia y Radioterapia- C.O.R, Montevideo
• 02:15pm - 03:30pm ET

  Trimodality Bladder Preservation Therapy Outcomes in Patients with Histologic Subtypes of Urothelial Carcinoma

  Speaker: Ting Martin Ma, MD, PhD - University of Washington, Seattle
• 02:15pm - 03:30pm ET

  TP53 Mutation is Independently Associated with Pathologic Lymph Node Involvement in Prostate Cancer: Implications for Elective Nodal Irradiation

  Speaker: Victor Lee, MD, BS - Yale New Haven Hospital, Middletown
• 02:15pm - 03:30pm ET

  Long-Term Outcomes and Toxicity Following Salvage Whole Gland or Focal HDR Brachytherapy for Recurrent Prostate Cancer: A Single-Institution Experience

  Speaker: Dina Elhabashy, MD, MS - Corewell Health William Beaumont University Hospital, Royal Oak
• 02:15pm - 03:30pm ET

  A Phase I/II Dose-Escalation Study Evaluating the Safety of 21 Gy, 23 Gy, and 25 Gy for High Dose Rate (HDR) Prostate Brachytherapy: An Interim Report

  Speaker: Michael Padgett, MD - Washington University in St. Louis, St. Louis
• 02:15pm - 03:30pm ET

  Clinical Validation of a Privacy-Preserving LLM for End-to-End CTCAE Toxicity Assessment in Prostate Cancer Radiotherapy

  Speaker: Ahmed Ghanem, MD, PhD - Henry Ford Cancer Institute/Alexandria University, Detroit
• 02:15pm - 03:30pm ET

  Initial Results of a Randomized Trial Comparing Full Bladder vs. Empty Bladder in Patients Receiving Definitive Radiation Therapy for Localized Prostate Cancer

  Speaker: Bradley Stish, MD, MS - Mayo Clinic, Rochester
• 02:15pm - 03:30pm ET

  Discordance between MRI-Targeted and Systematic Core Biopsy in Identifying the Highest-Grade Focus: Implications for Intraprostatic Boost

  Speaker: Chaewon Hwang, MD - Tufts Medical Center | Beth Israel Deaconess Medical Center, Boston
• 02:15pm - 03:30pm ET

  Safety of Spine Radiotherapy Delivered within 6 Months of Lu-177 PSMA Radioligand Therapy in Metastatic Prostate Cancer

  Speaker: Joshua Qian, MD - Memorial Sloan Kettering Cancer Center, New York
• 02:15pm - 03:30pm ET

  Intensity Modulated Proton Therapy (IMPT) for Localized Prostate Cancer: Disease Control Outcomes in Intermediate to Very-High Risk Patients

  Speaker: Marcio Fagundes, MD - Miami Cancer Institute, Miami
• 02:15pm - 03:30pm ET

  Gastrointestinal and Renal Adverse Events following Kidney SBRT for Renal Cell Carcinoma: Impact of Recent Systemic Therapy Use

  Speaker: Keaton Rummel, MD - Mayo Clinic College of Medicine and Science Rochester, Rochester
• 02:15pm - 03:30pm ET

  Clinicopathologic Predictors of PSMA-PET Detection, Recurrence Pattern, and Biochemical Outcome Following Salvage Radiotherapy after Radical Prostatectomy

  Speaker: Ramotallah Jubril, - Purdue University, West Lafayette
• 02:15pm - 03:30pm ET

  Impact of Preexisting Depression on Adherence to Androgen Deprivation Therapy and Radiation in High-Risk Prostate Cancer

  Speaker: Edmund Qiao, MD - University of California San Diego, San Diego
• 02:15pm - 03:30pm ET

  High-Throughput Dosimetric Profiling of Pelvic Organs at Risk and Lymphopenia in Prostate Radiotherapy

  Speaker: Lukasz Kuncman, MD, PhD - Fundacja im Jakuba Hrabiego Potockiego, Warszawa
• 02:15pm - 03:30pm ET

  Blood Urea Nitrogen as a Prognostic Biomarker In Bladder Cancer

  Speaker: Prakash Chaudhary, PhD - Cedars-Sinai Medical Center, Los Angeles
• 02:15pm - 03:30pm ET

  Wearable Artificial Intelligence Powered Device for Optimal Pelvic Radiation Therapy

  Speaker: Fan Zhu, MD, BS - Medical College of Wisconsin, Milwaukee
• 02:15pm - 03:30pm ET

  Radiomic Risk Stratification Using Pretreatment PSMA PET/CT Identifies Patients at Higher Risk for Biochemical Recurrence and Distant Metastases in Prostate Cancer

  Speaker: Lakshmi Rekha Narra, MD - Rutgers Cancer Institute of New Jersey, New Brunswick
• 02:15pm - 03:30pm ET

  Multicohort Validation of Genetic Variants Associated with Radiation-Induced Hematuria in Prostate Cancer Patients

  Speaker: Jung Hun Oh, PhD - Memorial Sloan Kettering Cancer Center, New York
• 02:15pm - 03:30pm ET

  Preoperative Biopsy Genomic Classifier Predicts Earlier Secondary Radiotherapy after Radical Prostatectomy: National Real-World Evidence

  Speaker: Thomas Kole, MD, PhD - Valley Health System, Paramus
• 02:15pm - 03:30pm ET

  Outcomes after Pelvic Radiotherapy and Androgen Deprivation Therapy for Pathologic Node-Positive Prostate Cancer in the PSMA PET Era

  Speaker: Sofia Romano, - Keck School of Medicine, University of Southern California, Los Angeles
• 02:15pm - 03:30pm ET

  Determining the Effect of Prostate Size on the Quality-of-Life Outcomes for Prostate Cancer Patients Undergoing Definitive Radiotherapy

  Speaker: Allen Khodab, BS - University of South Carolina, Columbia
• 02:15pm - 03:30pm ET

  Polygenic Scores as a Genetically Informed Approach to Prostate Cancer Risk Stratification

  Speaker: Daniel Sabater Minarim, MS - UCSD Health, La Jolla
• 02:15pm - 03:30pm ET

  Prediction Model Construction and Clinical Utility of Positive Surgical Margins in Apical Prostate Tumors Using Multimodal MRI

  Speaker: Yize Zhao, MD - Peking University First Hospital, Beijing
• 02:15pm - 03:30pm ET

  Comorbidity and Bladder Dose-Volume Interplay in Grade-Specific Late Hemorrhagic Radiation Cystitis Following Post-Prostatectomy Radiotherapy: An Asian Cohort

  Speaker: Hsing-Ju Li, MS - National Taiwan University Hospital, Taipei
• 02:15pm - 03:30pm ET

  Neoadjuvant Chemotherapy vs. Antibody Drug Conjugate/Immune Checkpoint Inhibitor Prior to Tri-Modality Treatment for Selected Patients with Muscle-Invasive Bladder Cancer

  Speaker: Shang-Bin Qin, MD - Peking University First Hospital, Beijing
• 02:15pm - 03:30pm ET

  The Dosimetric Advantages of Intensity-Modulated Proton Therapy (IMPT) in the Full Coverage Radiation of Primary and All Metastatic Lesions in Patients with Oligometastatic Prostate Cancer

  Speaker: Lin Ma, MD - Peking University First Hospital, Beijing
• 02:15pm - 03:30pm ET

  Impact of Clinical Factors on ¹⁸F-Piflufolastat and ¹⁸F-Flotufolastat Detection Rates in Patients with Recurrent Prostate Cancer Post-Prostatectomy: Results from an Intra-Patient Head-to-Head Study

  Speaker: Jack Andrews, MD - Mayo Clinic, Scottsdale
• 02:15pm - 03:30pm ET

  Survival Outcomes and Toxicity with Reduced-Dose ARPI Therapy: Rationale for the ENHANCE Phase III Trial

  Speaker: Ananya Choudhury, PhD, MA MRCP FRCR - The Christie NHS Foundation Trust and University of Manchester, Manchester
• 02:15pm - 03:30pm ET

  PRO-BOOST-N: Phase II/III Trial of Prostate-First vs. Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer

  Speaker: Mateusz Bilski, MD, PhD - Lublin Region Oncology Center, Lublin
• 02:15pm - 03:30pm ET

  Impact of Posterior PTV Margin on the Treatment Efficiency and Adverse Effects of Radical Radiotherapy for Prostate Cancer Patients

  Speaker: Lin Ma, MD - Peking University First Hospital, Beijing
• 02:15pm - 03:30pm ET

  Combination Low-Dose-Rate Brachytherapy and Stereotactic Body Radiation Therapy (SBRT) In Localized Intermediate- and High-Risk Prostate Cancer: A Single Institution Experience

  Speaker: Benjamin Tran, MD - Mount Sinai Hospital, New York
• 02:15pm - 03:30pm ET

  Development of Salvage Brachytherapy-Specific Genitourinary Toxicity Nomograms after Prostate Reirradiation

  Speaker: Mateusz Bilski, MD, PhD - Lublin Region Oncology Center, Lublin
• 02:15pm - 03:30pm ET

  Interfraction Positional Stability of a Biodegradable Balloon Rectal Spacer during Prostate SBRT

  Speaker: Tomer Charas, MD - Rambam Medical Center, Haifa
• 02:15pm - 03:30pm ET

  Internally Validated Survival Nomograms for Recurrence, Metastasis, and Overall Survival after Salvage Prostate Brachytherapy

  Speaker: Mateusz Bilski, MD, PhD - Lublin Region Oncology Center, Lublin
• 02:15pm - 03:30pm ET

  The Safety and Efficacy of PSMA-PET-Guided Comprehensive Radiotherapy for Oligo-Residual Disease after Treatment in High-Volume Metastatic Prostate Cancer

  Speaker: Qing-hua Peng, MD - Peking University First Hospital, Beijing
• 02:15pm - 03:30pm ET

  Post-Treatment PSMA PET as a Predictor of PSA Relapse in Primary Prostate Cancer

  Speaker: Tianyu Justin Yang, PhD - Rutgers Cancer Institute of New Jersey, New Brunswick
• 02:15pm - 03:30pm ET

  Stereotactic Magnetic Resonance-Guided Adaptive Radiotherapy for Prostate Cancer from Prospective Phase II Trial: Prostate vs. Prostate, pElvis and Metastases (SMART-P vs. SMART-PEM)

  Speaker: Meng Sun, - Department of Radiation Oncology, Cancer Hospital,Chinese Academy of Medical Sciences,Peking Union Medical College,Beijing,China, Beijing
• 02:15pm - 03:30pm ET

  Metastasis Directed Radiation Therapy for Oligometastatic and Oligoprogressive Renal Medullary Carcinoma

  Speaker: Shlok Mohanty, BS - McGovern Medical School,
• 02:15pm - 03:30pm ET

  Baseline Urinary Symptom Burden, but not DIL/CTV Ratio, Correlates with Late GU Toxicity After Single-Dose Prostate Radiotherapy with Simultaneous Integrated Dominant Intraprostatic Lesion Boost

  Speaker: Carlo Greco, MD - CCU, Lisbon
• 02:15pm - 03:30pm ET

  Impact of Locoregional Chemohyperthermia in Recurrent Non-Muscle-Invasive Bladder Cancer: Cohort Follow-Up Study

  Speaker: C. Paola Tello Valverde, MS - Amsterdam University Medical Center (AUMC), Amsterdam
• 02:15pm - 03:30pm ET

  Daily Adaptive RadioTherapy In Postoperative HypofrActionated Salvage RadiothERapy for Prostate Cancer Patients (DART-PHASER): Preliminary Results

  Speaker: Luca Nicosia, MD - Sacro Cuore don Calabria hospital, Negrar di Valpolicella
• 02:15pm - 03:30pm ET

  Stereotactic Body Radiotherapy in Medically Inoperable Urinary Tract Urothelial Carcinoma: A Retrospective Experience

  Speaker: Hiroshi Onishi, MD, PhD - University of Yamanashi, Chuo-shi 409-3898
• 02:15pm - 03:30pm ET

  Adaptive Kidney Irradiation: The Impact of CT-Based Adaptive Radiotherapy on Kidney Cancer SBRT Delivery

  Speaker: Elizabeth Ademuwagun, MD - Temple University Hospital/Fox Chase Cancer Center, Philadelphia
• 02:15pm - 03:30pm ET

  Sacral Plexus Dose Constraints in the SBRT Era: A Retrospective Analysis of Radiation-Induced Lumbosacral Plexopathy

  Speaker: Nan Zhao, MD, PhD - Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland
• 02:15pm - 03:30pm ET

  Impact of Prediagnostic Primary Care Utilization on Bladder Cancer Metastasis and Mortality

  Speaker: Nikitha Kalahasti, BS - University of California at San Diego, La Jolla
• 02:15pm - 03:30pm ET

  Patterns of Care and Survival in Cribriform Prostate Carcinoma in SEER

  Speaker: Jonathon Cummock, MD, PhD - Texas A&M University Naresh K. Vashisht College of Medicine, Humble
• 02:15pm - 03:30pm ET

  Toxicity and Efficacy of Radiotherapy with or without Pelvic Prophylactic Radiotherapy in Patients with Oligometastatic Prostate Cancer

  Speaker: Xin Qi, MD, MS - Peking University First Hospital, Beijing
• 02:15pm - 03:30pm ET

  What Is the Procedure-Related Complication Rate Associated with Iodinated Hydrogel Spacer Use in Prostate Radiotherapy? A Large Single-Center Experience

  Speaker: Paul Kelly, MD - UPMC Kildare Hospital, Clane
• 02:15pm - 03:30pm ET

  Evaluation of the Efficacy and Safety of Particle Therapy for Kidney Cancer through a Multicenter Registry Study and Meta-Analysis

  Speaker: Kentaro Nishioka, MD, PhD - Hokkaido University, Sapporo
• 02:15pm - 03:30pm ET

  APP4-Guided Selection of Active Surveillance vs. SBRT for Favorable-Risk Prostate Cancer: Pooled Prospective Registry and Trial Outcomes

  Speaker: Ruben Del Castillo, MD - Sunnybrook Odette Cancer Centre, Toronto
• 02:15pm - 03:30pm ET

  Precision Nutrition Enhances Radiotherapy by Exploiting MYC- and PTEN/AKT-Driven Metabolic Dependencies in Prostate Cancer

  Speaker: Shan Xu, MD - Thomas Jefferson University Hospital, Philadelphia
• 02:15pm - 03:30pm ET

  Retrospective Comparison of PULSAR vs. SAbR in Combination with Immunotherapy for Renal Cell Carcinoma

  Speaker: Casey Moore, BS - Department of Pathology, University of Texas Southwestern Medical Center, Dallas
• 02:15pm - 03:30pm ET

  Dosimetric Benefit of Online Adaptive Radiotherapy In Bladder Cancer

  Speaker: Goda Kalinauskaite, MD - Charite - Universitatsmedizin Berlin, Berlin
• 02:15pm - 03:30pm ET

  Evaluating Prostate Bed Dose Escalation in the Setting of Salvage Radiotherapy and ADT

  Speaker: Alexander Sasse, MD - UCSF Comprehensive Cancer Center, San Francisco
• 02:15pm - 03:30pm ET

  The Guiding Value of PSMA PET/CT Combined with Contrast-Enhanced Prostate MRI for Salvage Radiotherapy in Prostate Cancer Patients with Low PSA Levels: A Single-Center Exploratory Study

  Speaker: Le Mao, MD - Peking University First Hospital, Beijing
• 02:15pm - 03:30pm ET

  Effectiveness and Safety of Relugolix in Patients With Advanced Prostate Cancer Receiving Radiation Therapy: 6-Month Subgroup Analysis of the OPTYX Study

  Speaker: Daniel Spratt, MD - University Hospitals Seidman Cancer Center, Case Western Reserve University, Beachwood
• 02:15pm - 03:30pm ET

  SBRT for Oligoprogressive Metastatic Renal Cell Carcinoma: Results of a Single Institution Retrospective Analysis

  Speaker: Ahmed Nawwar, MD, MPH - University of Kansas Cancer Center, Kansas City
• 02:15pm - 03:30pm ET

  Dosimetric Feasibility of Genomically Stratified Dominant Lesion Boost In Two-Fraction Prostate SBRT

  Speaker: Nima Aghdam, MD, MS - NYU Langone Health, New York
• 02:15pm - 03:30pm ET

  Association of Pre-Treatment Sacral Bone Marrow Morphology with Radiation-Induced Lymphopenia in Prostate Cancer

  Speaker: Konrad Stawiski, MD - Medical University of Lodz, Lodz
• 02:15pm - 03:30pm ET

  Dosimetric Outcomes of Cytoreductive Stereotactic Body Radiotherapy (SBRT) for Metastatic Renal Cell Carcinoma (mRCC): Data from the CYTOSHRINK Trial

  Speaker: Laura Collie, MD, BS - Juravinski Cancer Center, Hamilton
• 02:15pm - 03:30pm ET

  Impact of Short-Term ADT on Survival in Unfavorable Intermediate-Risk Prostate Cancer Treated with Proton-Beam Radiotherapy - A Retrospective Cohort Study

  Speaker: Kayeong Shin, MD - MD Anderson Cancer Center, Houston
• 02:15pm - 03:30pm ET

  Erectile Dysfunction Severity as a Vascular Biomarker Predicting Cardiovascular Mortality in Patients with Prostate Cancer

  Speaker: Mutlay Sayan, MD - Brigham and Women's Hospital/Dana-Farber, Boston
• 02:15pm - 03:30pm ET

  Early Patient-Reported Outcomes following Two-Fraction Prostate SBRT with and without Dominant Lesion Boost

  Speaker: Vianca Santos, MPH - NYU Langone Health - Long Island, Mineola
• 02:15pm - 03:30pm ET

  A Comprehensive Population Study of Prostate MR-Linac SBRT: Quantifying Motion-Induced Duty Cycle Variations and Simulated Non-Gated Dosimetry

  Speaker: Kamal Singhrao, PhD - Brigham and Women's Hospital/Dana Farber Cancer Institute, Boston
• 02:15pm - 03:30pm ET

  Pelvic Radiotherapy Increases Severe Lymphopenia in Prostate Cancer

  Speaker: Kayeong Shin, MD - MD Anderson Cancer Center, Houston
• 02:15pm - 03:30pm ET

  Erectile Dysfunction Severity as a Clinical Marker of High-Grade Prostate Cancer at Presentation

  Speaker: Mutlay Sayan, MD - Brigham and Women's Hospital/Dana-Farber, Boston
• 02:15pm - 03:30pm ET

  Differences In Rectal Dosimetry between Implantable Rectal Spacer Options for Prostate Cancer Radiotherapy

  Speaker: Sean McCauley, MD - Mayo Clinic Arizona, Phonix
• 02:15pm - 03:30pm ET

  Analysis of SBRT for Oligoprogressive Renal Cell Carcinoma Lung Metastases: Impact on Distant Control, Systemic Therapy, and Survival Outcomes

  Speaker: Grace Song, BA - Cleveland Clinic Foundation, Cleveland
• 02:15pm - 03:30pm ET

  Renal Function Preservation after Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Multicenter Real-World Experience

  Speaker: Wojciech Majewski, MD, PhD - Radiotherapy Department, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice
• 02:15pm - 03:30pm ET

  Effect of Prostate-Specific Membrane Antigen PET/CT Guidance on Metastasis-directed Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer

  Speaker: John Chojnowski, MD, PhD - Hospital of the University of Pennsylvania, Philadelphia
• 02:15pm - 03:30pm ET

  Systematic Review of SBRT after Radical Prostatectomy in Prostate Cancer: Current Evidence and Clinical Outcomes in Both Adjuvant and Salvage Scenarios

  Speaker: Laith Samhouri, MD - Ludenscheid Klinikum, Ludenscheid
• 02:15pm - 03:30pm ET

  Dosimetric Impact of Intentional Proximal Seminal Vesicle Targeting In Low-Dose-Rate I-125 Prostate Brachytherapy Monotherapy

  Speaker: Piero Bettoli, MD, MS - Instituto Nacional del Cancer, Santiago
• 02:15pm - 03:30pm ET

  Effects of Prostate Auto-Planner on Plan Quality, Dosimetric Constraints, and Clinic Workflow: A Real World Comparison

  Speaker: Matthew Trotta, MD - University of Alabama at Birmingham, Birmingham
• 02:15pm - 03:30pm ET

  Spatial Immune Phenotyping Using Histo-Immuno-Radiomics Identifies Early Recurrence Profiles with Implications for Salvage Radiotherapy Stratification

  Speaker: Oluwaseyi Oderinde, PhD - Purdue University, West Lafayette
• 02:15pm - 03:30pm ET

  Longitudinal Characterization of Rectal Spacing Achieved by Two Commercial Rectal Spacer Products

  Speaker: Ryan Davis, MD - City of Hope National Medical Center, Duarte
• 02:15pm - 03:30pm ET

  Toxicity Outcomes and Patterns of Failure after Whole vs. Partial Gland HDR Brachytherapy as Salvage Treatment for Recurrent Prostate Cancer

  Speaker: Paul Armstrong, MD - University of Maryland School of Medicine, Baltimore
• 02:15pm - 03:30pm ET

  Hypofractionated Salvage Radiation Therapy in Biochemical Recurrence of Prostate Cancer: Acute Toxicity and Timing Insights

  Speaker: Nicole Arbex, - RadioSerra Radiation Therapy, Sao Paulo
• 02:15pm - 03:30pm ET

  Sexual Function after Radiation Therapy: Long-Term Outcomes and Real-World Effectiveness of Sexual Medicines and Devices

  Speaker: Sophia Kim-Wang, MD, PhD - University of Chicago, Chicago
• 02:15pm - 03:30pm ET

  Tumor Control and Normal Tissue Complication Probability Modeling for High Dose Rate Brachytherapy Followed by 5-Fraction SBRT Treatment of Unfavorable Intermediate or High-risk Prostate Cancer Patients with Biodegradable Hydrogel Rectal Spacer Placement

  Speaker: Ke Huang, PhD, MS - Indiana University, Indianapolis
• 02:15pm - 03:30pm ET

  Adaptive Planning in a Prospective Bladder Cancer Trial: Dosimetric Outcomes

  Speaker: Katherine Amarell, MD, BS - Cleveland Clinic Foundation, Cleveland
• 02:15pm - 03:30pm ET

  Prospective Phase 1 Clinical Trial of CBCT-Guided Adaptive SBRT to the Prostate and Pelvic Nodes with Simultaneous Integrated Boost to the MR-Detected Nodule for Patients with High-Risk and Unfavorable Intermediate-Risk Prostate Cancer

  Speaker: Andrew Willett, MD - Washington University in St. Louis School of Medicine, St Louis
• 02:15pm - 03:30pm ET

  Hydrogel Spacers Hold the Line: Rectal Wall Infiltration is Rare in Prostate SBRT

  Speaker: Mihir Karande, MD - Fox Chase Cancer Center, Philadelphia
• 02:15pm - 03:30pm ET

  Long-Term Efficacy and Safety Outcomes of Dose-Escalated SBRT for Prostate Cancer

  Speaker: John Starner, DO - Northwell Health, Lake Success
• 02:15pm - 03:30pm ET

  Surface-Guided End-Exhale Breath-Hold for Primary Kidney Cancer Stereotactic Ablative Radiotherapy

  Speaker: Siqiu Wang, PhD - University of Texas Southwestern Medical Center, Dallas
• 02:15pm - 03:30pm ET

  Comparative Analysis of Perirectal Spacer Quality for Two FDA-Approved Products

  Speaker: Edmond Yaghoubian, MD - UPMC, Pittsburgh
• 02:15pm - 03:30pm ET

  Beyond Margins and Stage: A DNA Damage and Cell-Cycle Checkpoint Transcriptional Phenotype Identifies Durable Benefit from Adjuvant Radiotherapy In Adrenocortical Carcinoma

  Speaker: Andrew Willett, MD - Washington University in St. Louis School of Medicine, St Louis
• 02:15pm - 03:30pm ET

  Cross-Continental Transcriptomic Evaluation of a Multimodal AI-Based Biomarker in Localized Prostate Cancer

  Speaker: Samantha Webking, MD - Moffitt Cancer Center, Tampa
• 02:15pm - 03:30pm ET

  Clinical Outcomes of Rectal Wall Infiltration Following Hydrogel Spacer Placement: A Single-Institution Retrospective Study

  Speaker: Zakaria El Kouzi, MD - MD Anderson Cancer Center, Houston
• 02:15pm - 03:30pm ET

  Stereotactic Body Proton Therapy for Primary Kidney Tumors: Early Outcomes from a Community Cancer Center

  Speaker: Chiachien Wang, MD, PhD - University of Texas Southwestern Medical Center, Dallas
• 02:15pm - 03:30pm ET

  Morphological-Dosimetric Model for Adaptive Radiotherapy Triggering in Bladder Cancer Radiotherapy

  Speaker: Sijuan Huang, - Sun Yat-sen University Cancer Center, Guangzhou
• 02:15pm - 03:30pm ET

  Radiotherapy Fractionation and Travel Burden in Prostate Cancer: A National Analysis of Access, Time Savings and Environmental Impact

  Speaker: Mohyeddine El Sayed, MD - Medical University of South Carolina, Charleston
• 02:15pm - 03:30pm ET

  PSMA PET Response Dynamics after 177Lu-PSMA Radiopharmaceutical Therapy and External Beam Radiotherapy

  Speaker: Arnav Rao, BA - Stanford University School of Medicine, Stanford
• 02:15pm - 03:30pm ET

  Oncologic Outcomes and Toxicity of PULSAR-Based Stereotactic Ablative Radiotherapy (SAbR) with Immunotherapy in Metastatic Urothelial Carcinoma

  Speaker: Yash Soni, MD, BS - UT Southwestern Medical Center, Dallas
• 02:15pm - 03:30pm ET

  Characterizing the Consult to CT-Simulation Interval in the Setting of Screening Colonoscopy Prior to Prostate Radiotherapy in a VA Patient Population

  Speaker: Joan Lee, MD - University Hospitals Cleveland Medical Center, Cleveland
• 02:15pm - 03:30pm ET

  Real World Experience of Stereotactic Body Radiotherapy for Carcinoma Prostate in a Tertiary Care Cancer Center in North India

  Speaker: Lincoln Pujari, MD - Mahamana Pandit Madan Mohan Malaviya Cancer Centre, Varanasi
• 02:15pm - 03:30pm ET

  Effect of Pelvic Radiation on Systemic Gene Expression Changes in a Prospective Study of Non-Metastatic Prostate Cancer

  Speaker: Benjamin George, - University of Iowa Carver College of Medicine,
• 02:15pm - 03:30pm ET

  The Association between Disease Control and Novel Pathologic or Radiographic Risk Factors in Intermediate-Risk Prostate Cancer (IR-PCa)

  Speaker: Beck French, - Department of Radiation Oncology, The Ohio State University Comprehensive Cancer Center, Columbus
• 02:15pm - 03:30pm ET

  Decipher Immune Microenvironment Signatures Predict Radiation Toxicity In Prostate Cancer: A Single-Institution Analysis

  Speaker: John Starner, DO - Northwell Health, Lake Success
• 02:15pm - 03:30pm ET

  Identification of Key Clinical and Dosimetric Predictors for Acute Treatment-Induced Toxicity following Postoperative Prostate Cancer Radiotherapy

  Speaker: Qian Man, MD - Peking University Third Hospital, Beijing
• 02:15pm - 03:30pm ET

  Social Determinants of Health and Psychological Distress in Prostate Cancer Patients Undergoing Radiation Therapy: A Prospective Cohort Study

  Speaker: Teresia Perkins, BS - Boston University School of Medicine (BUSM), Boston
• 02:15pm - 03:30pm ET

  A Tiered Plan-Library-First Workflow Reduces Triggered Online Adaptive Radiotherapy in Postprostatectomy Radiotherapy

  Speaker: Xuemin Li, MD - Peking University Third Hospital, Beijing
• 02:15pm - 03:30pm ET

  Prospective Geometric Assessment for PTV Margin Adaptation in Fiducial-Guided Prostate SBRT

  Speaker: Zuzana Cermakova, MD - University Hospital Ostrava, Ostrava
• 02:15pm - 03:30pm ET

  Anatomy-Guided Maximized-Volume Spatially Fractionated Radiotherapy Versus Conventional SABR in Oligometastatic Renal Cell Carcinoma: A Retrospective Review of a Prospective Cohort Study

  Speaker: Shanshi Li, PhD - Peking University First Hospital, Beijing
• 02:15pm - 03:30pm ET

  A Prospective Study on Tumor Detection and PET-guided Radiotherapy Treatment Planning with PSMA-targeted Flotufolastat F-18 Imaging on a Biology-guided Radiotherapy Machine

  Speaker: Chunhui Han, PhD - City of Hope National Medical Center, Duarte
• 02:15pm - 03:30pm ET

  A Prospective Observational Trial of Single Fraction Stereotactic Ablative Body Radiotherapy for Oligometastatic Patients (SONIC-O): Preliminary Results

  Speaker: Federico Colombo, MD - Aou Parma, Parma
• 02:15pm - 03:30pm ET

  Real-World Outcomes of [¹⁷⁷Lu]Lu-PSMA-617 (¹⁷⁷Lu-PSMA-617) Treatment Extension in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC): A PRostatE Cancer dISease observatION (PRECISION) Database Analysis

  Speaker: Elisabeth Heath, MD - Mayo Clinic, Scottsdale
• 02:15pm - 03:30pm ET

  Efficacy and Safety of Salvage Re-Irradiation in Oligoprogressive Prostate Cancer

  Speaker: Huan Zhang, MD - Peking University First Hospital, Beijing
• 02:15pm - 03:30pm ET

  Assessing the Prevalence of Pathogenic Germline Variants in Prostate Cancer Patients Managed with Radiation Therapy

  Speaker: Adetolani Odogiyon, BS - Massachusetts General Hospital, Winchester
• 02:15pm - 03:30pm ET

  Long-Term Outcomes after Trimodality Therapy for Muscle-Invasive Bladder Cancer: A Single Institution Experience

  Speaker: Panos Papanikolaou, MD - Johns Hopkins Hospital, Baltimore
• 02:15pm - 03:30pm ET

  External Validation of a Germline Genetic Risk Score for Genitourinary Adverse Events after Prostate Radiotherapy

  Speaker: George Xu, PhD - University of California San Diego, San Diego
• 02:15pm - 03:30pm ET

  Intravesical Prostatic Protrusion: Exploring a Novel Imaging Biomarker for Late Genitourinary Outcomes following Prostate SBRT

  Speaker: Makoto Ito, MD, PhD - Aichi Medical University Hospital, Nagakute
• 02:15pm - 03:30pm ET

  Outcomes of Carbon-Ion Radiotherapy for Very High-Risk Prostate Cancer in a Contemporary Consecutive Cohort

  Speaker: Hiraku Sato, MD, PhD - Yamagata University, Yamagata
• 02:15pm - 03:30pm ET

  Diagnostic Performance of mpMRI and PSMA PET In Local Intraprostatic Radiorecurrent Prostate Cancer: A Radiologic-Pathologic Correlation Study

  Speaker: Esther Yu, MD - UCLA David Geffen School of Medicine/UCLA Medical Center, Los Angeles
• 02:15pm - 03:30pm ET

  PRO-BOOST-LC: Phase II/III Trial of Whole-Gland Boost Strategies vs. SBRT Monotherapy in PSMA-Staged Localized and Locally Advanced Prostate Cancer

  Speaker: Mateusz Bilski, MD, PhD - Lublin Region Oncology Center, Lublin
• 02:15pm - 03:30pm ET

  Vascular Optimized Radiotherapy Tuned to Critical Structures for Erectile Function Using High-Precision X-Ray Treatment (VORTEX) - A Prospective Phase III RCT of Neurovascular-Sparing SBRT

  Speaker: Jonathan Massachi, MD, MS - University of California, Los Angeles, Los Angeles
• 02:15pm - 03:30pm ET

  A Phase II Trial In Progress: Alpha-emitting radioNucliDe or Beta-Emitting RadiOnuclide Combined With MEtastasis-Directed Stereotactic Body Radiotherapy for Oligorecurrent Prostate Adenocarcinoma (ANDROMEDA)

  Speaker: Kekoa Taparra, MD, PhD, MPH - UCLA Health, Los Angeles
• 02:15pm - 03:30pm ET

  The Performance of PET, Multiparametric MRI and Transperineal Prostate Biopsy in Identification of Intraprostatic Tumor Deposits after Prostate Radiation Therapy

  Speaker: R. Hsi, MD - Fred Hutch Cancer Center Peninsula, Poulsbo
• 02:15pm - 03:30pm ET

  Clinical Predictors of Long-Term Urinary Morbidity Following Combination Radiation Therapy for Prostate Cancer

  Speaker: Ryan Lee, - Urology of Greater Atlanta, Stockbridge
• 02:15pm - 03:30pm ET

  Detection and Localization of Unfavorable-Histology Prostate Cancer Using MRI and Whole-Mount Histopathology

  Speaker: Mariluz Rojo Domingo, MS - Department of Bioengineering, UC San Diego Jacobs School of Engineering, La Jolla
• 02:15pm - 03:30pm ET

  Prospective Study of Rectal Spacer Application with Adaptive MR-Guided SBRT in cT3a-T3b Prostate Cancer

  Speaker: Oilei Wong, PhD - Hong Kong Sanatorium and Hospital, Hong Kong
• 02:15pm - 03:30pm ET

  Skeletal-Related Events after Radiotherapy for Non-Spine Bone Metastases in Renal Cell Carcinoma

  Speaker: Harshath Gupta, MD - MD Anderson Cancer Center, Houston
• 02:15pm - 03:30pm ET

  Long-Term Changes in Sexual Function After Carbon Ion Radiotherapy for Localized Prostate Cancer: A Five-Year Prospective Study

  Speaker: Yoshiyuki Miyazawa, MD - Gunma University Department of Urology, Maebashi
• 02:15pm - 03:30pm ET

  Age Is Associated With PSA Kinetics but Not With Oncological Outcomes After Low-Dose-Rate Brachytherapy

  Speaker: Yasushi Nakai, MD, PhD - Nara Medical University, Kashihara
• 02:15pm - 03:30pm ET

  Impact of Prostate-Specific Membrane Antigen Scans on Treatment Decision-Making in Patients with Metastatic Prostate Cancer in Clinical Practice: A PRostatE Cancer dISease observatION (PRECISION) Database Analysis

  Speaker: Daniel George, MD - Duke University School of Medicine, Durham
• 02:15pm - 03:30pm ET

  Mechanistic Insights into Radiopharmaceutical Therapy Resistance through Bayesian Analysis of Circulating Tumor Cell Transcriptomes

  Speaker: Keisuke Otani, MD, PhD - Massachusetts General Hospital, Charlestown
• 02:15pm - 03:30pm ET

  Lifetime Risk of Androgen Deprivation Therapy after Active Surveillance for Prostate Cancer

  Speaker: James Janopaul-Naylor, MD - Memorial Sloan Kettering Cancer Center, New York
• 02:15pm - 03:30pm ET

  Clinical vs. MRI Risk Signals In Intermediate-Risk Prostate Cancer Treated with Radiotherapy: Associations with PSA Density and Radiographic ECE/SVI

  Speaker: James Janopaul-Naylor, MD - Memorial Sloan Kettering Cancer Center, New York
• 02:15pm - 03:30pm ET

  Interfractional Dosimetric Variations During MR-guided Radiotherapy as Predictors of Genitourinary Toxicity in Prostate Cancer

  Speaker: Jessica Hossa, MD, MS, BS - Allegheny General Hospital, Pittsburgh
• 02:15pm - 03:30pm ET

  Androgen Deprivation Therapy (ADT) and Radiotherapy (RT) with Imaging Evaluation Longitudinally (ARIEL): Implications of Neoadjuvant ADT for Focal RT Boost In Prostate Cancer

  Speaker: Mariluz Rojo Domingo, MS - Department of Bioengineering, UC San Diego Jacobs School of Engineering, La Jolla
• 02:15pm - 03:30pm ET

  Real-World Outcomes of Daily CBCT-Based Online Adaptive Radical-Intent Bladder Radiotherapy

  Speaker: Olabisi Ogunbiyi, - Royal Surrey County Hospital, London
• 02:15pm - 03:30pm ET

  Is This the Right Fossa? Verification of Prostate Fossa Contouring Volumes Using 18F-Fluciclovine PET/CT

  Speaker: Adam Eakin, MD - Oregon Health and Science University, Portland
• 02:15pm - 03:30pm ET

  FocaSaBra: A Prospective Phase II Trial of Focal Salvage Brachytherapy for Locally Recurrent Prostate Cancer after Radiotherapy

  Speaker: Wojciech Burchardt, MD, PhD - Greater Poland Cancer Centre, Poznan
• 02:15pm - 03:30pm ET

  Circulating Tumor DNA Dynamics in Oligometastatic Urothelial Carcinoma Treated with Stereotactic Body Radiation Therapy

  Speaker: Dekuang Zhao, DO, PhD - Moffitt Cancer Center, Tampa
• 02:15pm - 03:30pm ET

  Phase 1 Trial of ¹⁷⁷Lu -rhPSMA-10.1 Following PSMA-PET-Guided Post-Prostatectomy Salvage Radiotherapy: Early Response Assessment

  Speaker: Ashesh Jani, MD, MS, FASTRO - Emory University, Atlanta
• 02:15pm - 03:30pm ET

  Prostate Hypofractionation over 20 Years: Long-Term Results from a Single Institution

  Speaker: Katherine Amarell, MD, BS - Cleveland Clinic Foundation, Cleveland
• 02:15pm - 03:30pm ET

  Quantitative Digital Pathology Defines Immune Activation Following Aglatimagene Besadenovec Immunotherapy in Localized Prostate Cancer

  Speaker: Francesca Barone, MD, PhD - Candel Therapeutics, Inc., Needham
• 02:15pm - 03:30pm ET

  Real-World Comparison of Initial Local Treatment Strategies for Gleason Grade 5 Prostate Cancer: Radiotherapy vs. Surgery Cohort Study

  Speaker: Le Mao, MD - Peking University First Hospital, Beijing
• 02:15pm - 03:30pm ET

  A Radiomics Based Approach for Predicting Prostate Cancer in PIRADS 3 Lesions on Multi-Parametric MRI

  Speaker: Rikhil Makwana, - Molecular Imaging Branch, National Cancer Institute, Bethesda
• 02:15pm - 03:30pm ET

  A Confirmative Study of Quantitative Imaging Biomarkers for PSMA-RLT Response and Toxicity

  Speaker: Vincent Li, BS - University of Wisconsin Madison School of Medicine and Public Health, Madison
• 02:15pm - 03:30pm ET

  SBRT for Intermediate and High-Risk Prostate Cancer without Fiducials: A Phase II Clinical Trial

  Speaker: Firas Almomen, MBBS - King Saud University Medical City, Riyadh
• 02:15pm - 03:30pm ET

  Prognostic Value of Lesions with Low PSMA Uptake in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing PSMA-RLT

  Speaker: Jonathan Benson, - University of Wisconsin Department of Human Oncology, Madison
• 02:15pm - 03:30pm ET

  Association of 22-Gene Genomic Classifier with ADT Use with Secondary Radiotherapy: A National Real-World Analysis

  Speaker: Andrew Barsky, MD - Hospital of University of Pennsylvnia, Philadelphia
• 02:15pm - 03:30pm ET

  National Utilization and Cost Patterns of Trimodality Therapy vs. Radical Cystectomy for Muscle-Invasive Bladder Cancer in the United States

  Speaker: Rod Carlo Columbres, DO - Department of Radiation Oncology, Winship Cancer Institute, Emory University, Atlanta
• 02:15pm - 03:30pm ET

  Assessment of CT Simulation-Based Prostate Radiotherapy Plan Robustness Using Serial Cone-Beam CT

  Speaker: Sonia Targ, MD, MS - Kaiser Permanente Los Angeles Medical Center, Los Angeles
• 02:15pm - 03:30pm ET

  Phase I Dose-Escalation of Hypofractionated Pelvic Nodal Proton Radiotherapy with Simultaneous Integrated Prostate Boost

  Speaker: Yomna Khamis, MD - University of Maryland, Baltimore
• 02:15pm - 03:30pm ET

  Safety and Feasibility of Nimotuzumab Combined with Gemcitabine and SABR-Boosted Concurrent Radiotherapy for Muscle Invasive Bladder Cancer: Initial Results from a Phase I/II Trial

  Speaker: Shangbin Qin, MD - Peking University First Hospital, beijing
• 02:15pm - 03:30pm ET

  Determinants of Kidney and Tumor Dose In Single-Timepoint ¹⁷⁷Lu-PSMA-617 Dosimetry

  Speaker: Srikrishna Tirumalareddy, - Thomas Jefferson University, Philadelphia
• 02:15pm - 03:30pm ET

  Secondary Lung Tumor in Localized Prostate Cancer Treated with Radiotherapy ± Androgen Depletion Therapy: Long-Term Data from Two Phase III Trials

  Speaker: Abdenour Nabid, MD - CHUS, Sherbrooke
• 02:15pm - 03:30pm ET

  Genitourinary Dosimetry and Early Urinary Quality of Life in a Randomized Prostate SAbR Trial with Planned Dose Heterogeneity

  Speaker: Kishan Pithadia, MD, BS - UT Southwestern Medical Center, Dallas
• 02:15pm - 03:30pm ET

  Improved Correction of Anatomical Distortion in Diffusion-Weighted Prostate MRI

  Speaker: Joshua Kim, BS - Loma Linda University School of Medicine, Vancouver
• 02:15pm - 03:30pm ET

  Radiotherapy for Localized and Metastatic Neuroendocrine Prostate Cancer

  Speaker: Carson Jones, - Brody School of Medicine at Eastern Carolina University, Greenville
• 02:15pm - 03:30pm ET

  Stereotactic Magnetic Resonance-Guided Adaptive Radiation Therapy (SMART) for Pelvic Reirradiation: A Phase 1/2 Trial

  Speaker: Alexander Droznin, - Brigham and Women's Hospital/ Dana Farber Cancer Institute, Boston
• 02:15pm - 03:30pm ET

  Radiomic Analysis of Pre-Treatment PSMA PET/CT for Prognostic Stratification in Patients with Oligometastatic Castration-Sensitive Prostate Cancer

  Speaker: Yufeng Cao, PhD - University of Maryland Central Maryland Radiation Oncology, Columbia
• 02:15pm - 03:30pm ET

  What Matters Most to Patients with Localized Prostate Cancer: Prospective Preference Data from a Statewide Consortium

  Speaker: Joseph Tang, MD - University of Michigan, Ann Arbor
• 02:15pm - 03:30pm ET

  Rising Utilization of Hyperbaric Oxygen Therapy for Radiation-Related Genitourinary Injury: A 10-Year Institutional Analysis

  Speaker: Sasha Ebrahimi, MD, PhD - UCLA Radiation Oncology, Los Angeles
• 02:15pm - 03:30pm ET

  Clinical Outcomes and Toxicities of Proton Beam Therapy for Testicular Seminoma: Results from the Proton Collaborative Group Prospective Registry

  Speaker: Lifei Zhu, MD, PhD - Montefiore Medical Center/Albert Einstein College of Medicine, Bronx
• 02:15pm - 03:30pm ET

  Understanding Demographic and Geographic Trends in DECIPHER Genomic Scores

  Speaker: Mathew Lin, BS - Dartmouth Geisel School of Medicine, Lebanon
• 02:15pm - 03:30pm ET

  Therapeutic Ratio of Seminal Vesicle Sparing vs. Inclusion in Prostate Stereotactic Body Radiation Therapy: A Propensity Score-Matched Competing Risks Analysis

  Speaker: Van Ton Tran, MD, MS - Military Hospital 103, Vietnam Military Medical University, Hanoi
• 02:15pm - 03:30pm ET

  Trimodality Therapy for Muscle-Invasive Bladder Cancer: Two Ways to the Same Target

  Speaker: Wojciech Majewski, MD, PhD - Radiotherapy Department, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice
• 02:15pm - 03:30pm ET

  Safety and Clinical Outcomes of Combining Radiotherapy with Lutetium-177-PSMA Therapy in Metastatic Castrate-Resistant Prostate Cancer

  Speaker: Patrick Carriere, MD, PhD - MD Anderson Cancer Center, Houston
• 02:15pm - 03:30pm ET

  Preliminary Results of a Prospective Study Investigating the Relationship between Change in PET Signal and Changes in Pathology Pre- to Mid-Treatment In High Risk Prostate Cancer

  Speaker: Daniela Duenas, - University of Wisconsin School of Medicine and Public Health, Madison
• 02:15pm - 03:30pm ET

  Magnetic Resonance Imaging (MRI) Radiomics that Predicts the Treatment Outcome in a Phase 2 Trial of Ra-223 Combined with Stereotactic Body Radiation Therapy and Androgen Deprivation Therapy (ADT) for Oligometastatic Castrate Sensitive Prostate Cancer

  Speaker: Kun Qing, PhD - City of Hope National Medical Center, Duarte
• 02:15pm - 03:30pm ET

  Comparable Early Outcomes With Moderately Hypofractionated Versus Conventional Secondary Radiotherapy After Prostatectomy

  Speaker: Kendall Garrett, - Case Western Reserve School of Medicine, Cleveland
• 02:15pm - 03:30pm ET

  MR-Guided Stereotactic Radiotherapy for Oligometastatic Prostate Cancer: Toward Optimal Patient Selection

  Speaker: Levi Burns, MD - University of Toronto, Toronto
• 02:15pm - 03:30pm ET

  Optimizing Perirectal Spacer Use: Risk Factors for Rectal Toxicity and Bowel Quality of Life after Hypofractionated Radiation Therapy for Prostate Cancer

  Speaker: Mira Patel, MD, BS - UChicago Medicine, Chicago
• 02:15pm - 03:30pm ET

  Clinical Impact and Concordance of Three Advanced Risk Stratification Tools for ADT Decision-Making In Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer

  Speaker: Shera Feinstein, MD - UC Irvine Health, Orange
• 02:15pm - 03:30pm ET

  Evaluating Reduced PTV Margins Enabled by MR-Linac Comprehensive Motion Management (CMM) in Prostate Stereotactic Radiotherapy (SBRT): Dosimetric and Clinical Implications

  Speaker: Ho Lam Lisa Chan, MS, RT - Hong Kong Sanatorium and Hospital, Hong Kong
• 02:15pm - 03:30pm ET

  Role of Salvage Radiotherapy in a "PRESTO-Like" Cohort of Patients with High Risk, PET Negative, Hormone-Sensitive Prostate Cancer

  Speaker: Giuseppe Sanguineti, MD - IRCCS “Regina Elena” National Cancer Institute, Rome
• 02:15pm - 03:30pm ET

  Impact of ⁶⁸Ga-PSMA PET/CT Staging on Metastasis-Free and Cancer-Specific Survival after Definitive Radiotherapy for High-Risk Prostate Cancer

  Speaker: Cem Onal, MD - Baskent University Faculty of Medicine, Department of Radiation Oncology, Ankara, Turkey, ankara
• 02:15pm - 03:30pm ET

  Late Genitourinary Toxicity after Definitive Radiotherapy with or without Simultaneous Integrated Boost In Post-TURP Prostate Cancer: A Competing-Risk Study

  Speaker: Huseyin Cem Onal, MD - Baskent University Faculty of Medicine, Adana
• 02:15pm - 03:30pm ET

  Impact of Extended Pelvic Lymph Node Dissection on Outcomes in High-Risk Prostate Cancer Patients Receiving Postoperative Pelvic Radiotherapy: A Secondary Analysis of a Prospective Study

  Speaker: Xueying Ren, MD - Radiation of Oncology, Peking University First Hospital, Beijing
• 02:15pm - 03:30pm ET

  Sequential Administration of PD-1-laIL2 before Radiotherapy Primes Anti-Tumor Immunity and Optimizes Outcomes in a Metastatic Prostate Cancer Model

  Speaker: Huizhu Chen, MD - Peking University First Hospital, Beijing
• 02:15pm - 03:30pm ET

  Impact of Sequence and Timing of Triplet Therapy on Outcomes in High Gleason Score Metastatic Hormone-Sensitive Prostate Cancer: A Long-Term Real-World Study

  Speaker: Huizhu Chen, MD - Peking University First Hospital, Beijing
• 02:15pm - 03:30pm ET

  Effect of PSMA PET/CT Image Review as a Visual Navigation Aid in a Vulnerable Prostate Cancer Population

  Speaker: Kritika Subramanian, MD, MS - Montefiore Medical Center/Albert Einstein College of Medicine, Bronx
• 02:15pm - 03:30pm ET

  The Evolution of Prostate Cancer Presentation

  Speaker: Jilcha Feyisa, MD, MPH - Dartmouth-Hitchcock Medical Center, Lebanon
• 02:15pm - 03:30pm ET

  Comparison of Urinary Toxicity in Prostate Cancer Patients Undergoing External Beam Radiation Therapy With High-Dose vs. Low-Dose Brachytherapy Boost

  Speaker: Catherine Drovetsky, - University of Maryland School of Medicine, Baltimore
• 02:15pm - 03:30pm ET

  A Single Institution Experience Comparing Outcomes of Muscle Invasive Bladder Cancer of Urothelial or Alternative Histology Treated with Trimodality Therapy

  Speaker: Celina Chiodo, MD, MS - Moffitt Cancer Center, Tampa
• 02:15pm - 03:30pm ET

  Salvage HDR Brachytherapy for Locally Recurrent Prostate Cancer after Radiotherapy: Long-Term Outcomes and Predictive Factors

  Speaker: Wojciech Burchardt, MD, PhD - Greater Poland Cancer Centre, Poznan
• 02:15pm - 03:30pm ET

  The Role of Stereotactic Body Radiotherapy in Oligoprogressive Renal Cell Carcinoma: A Site-Specific Analysis of the Phase II RADIANT Trial

  Speaker: Neelabh Rastogi, MD - University of Toronto, Toronto
• 02:15pm - 03:30pm ET

  Prognostic Impact of Grade Group Discordance between MRI-Targeted and Systematic Biopsy Cores in Localized Prostate Cancer

  Speaker: Hyo Jin Ryu, DO - University of Michigan Hospital, Ann Arbor
• 02:15pm - 03:30pm ET

  Physician and Patient Reported Outcomes Following Contemporary Image-Guided Intensity Modulated Proton Therapy for Prostate Cancer: Results from the Prospective PRO-Cube Study

  Speaker: Srinivas Chilukuri, MD, MBBS - Apollo Proton Cancer Centre, Chennai
• 02:15pm - 03:30pm ET

  Dosimetric Correlates of Long-Term Quality of Life In a Randomized Trial of Prostate Radiation Therapy with and without a Hydrogel Spacer

  Speaker: Abdallah Mohamed, MD, PhD - Baylor College of Medicine, Houston
• 02:15pm - 03:30pm ET

  Dosimetric Assessment of ¹77Lu-PSMA-617 and SBRT In Locally Advanced Prostate Cancer: Interim Dosimetry of the STARLiT Trial

  Speaker: Qing Li, MD, PhD - UH Cleveland Medical Center, Cleveland
• 02:15pm - 03:30pm ET

  Long-Term Oncologic Outcomes Following LDR Prostate Brachytherapy: 10-Year Overall and Biochemical Control with Extended Follow-Up

  Speaker: Erin Baker, MD - University of Manitoba, Winnipeg
• 02:15pm - 03:30pm ET

  PSA Kinetics and Functional MRI as Complementary Biomarkers of Response after MR-Guided Focal Boost Radiotherapy for High-Risk Prostate Cancer

  Speaker: Haruo Inokuchi, MD, PhD - osaka metropolitan university, Osaka-city
• 02:15pm - 03:30pm ET

  Low Acute Toxicity with Online CT-Based Adaptive Radiation Therapy for Prostate Cancer

  Speaker: Paul Ramia, MD - Cleveland Clinic Abu Dhabi, Abu Dhabi
• 02:15pm - 03:30pm ET

  Deep Learning Auto-Segmentation of the Internal Pudendal Artery on CT: Dosimetric Validation Against MRI-Informed Ground Truth Contours

  Speaker: Omar Awad, MD, MS - Baylor College of Medicine, Houston
• 02:15pm - 03:30pm ET

  Benchmarking Multimodal AI-Predicted Metastasis and Prostate Cancer-Specific Mortality Risk Against STAR-CAP: A 20,000-Patient Commercial Experience

  Speaker: Daniel Spratt, MD - University Hospitals Seidman Cancer Center, Case Western Reserve University, Beachwood
• 02:15pm - 03:30pm ET

  A Phase II Trial of MRI-Mapped Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The Miami MAPS Trial

  Speaker: David Lee, MD - Sylvester Comprehensive Cancer Center, University of Miami, Miami
• 02:15pm - 03:30pm ET

  Local Radiotherapy and ADT Monotherapy for Low-Volume mHSPC: Real-World Outcomes in the Era of PSMA PET-CT Staging

  Speaker: Yuen Hang Lau, MBBS - Queen Elizabeth Hospital, Hong Kong